Skip to main content
. 2022 Oct 31;13:1029891. doi: 10.3389/fneur.2022.1029891

Figure 2.

Figure 2

HMGB1 can be actively secreted by immune cells or passively secreted by necrotic or damaged cells. HMGB1 binds to RAGE and TLR4 to activate downstream signaling pathways, resulting in the upregulation of cytokines by pro-inflammatory cells. As HMGB1 antagonists, GL and EP can inhibit the release of HMGB1. The anti-HMGB1 mAb neutralizes HMGB1.